Sanjay Shukla - Feb 3, 2023 Form 4 Insider Report for aTYR PHARMA INC (LIFE)

Role
President and CEO, Director
Signature
/s/ Nancy E. Denyes, attorney-in-fact
Stock symbol
LIFE
Transactions as of
Feb 3, 2023
Transactions value $
$0
Form type
4
Date filed
2/6/2023, 05:57 PM
Previous filing
Nov 21, 2022
Next filing
Feb 21, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LIFE Common stock Options Exercise +10.4K +20.42% 61.2K Feb 3, 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LIFE Restricted Stock Unit Options Exercise $0 -10.4K -25% $0.00 31.1K Feb 3, 2023 Common Stock 10.4K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares acquired upon the vesting of restricted stock units (RSUs) granted to the Reporting Person on February 3, 2022.
F2 Restricted stock units convert into common stock on a one-for-one basis.
F3 The RSUs vest in four equal annual installments beginning on February 3, 2023, such that the RSUs will fully vest on February 3, 2026. The RSUs are subject to accelerated vesting upon termination without cause upon a change of control of the Issuer.